Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AP 12009: Phase I/II

In an ongoing Phase I/II dose-escalation study, AP 12009 was safe and

Read the full 128 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE